Romosozumab in Postmenopausal Women with Low Bone Mineral Density

20141,212 citationsJournal Article

Authors

Michael R. McClung · Bone Health and Osteoporosis Foundation

Andreas Grauer · Amgen (United States)

Steven Boonen

Michael A. Bolognese

Jacques P. Brown · Centre hospitalier universitaire de Québec

Adolfo Díez‐Pérez · Universitat Autònoma de Barcelona

Bente Langdahl · Aarhus University Hospital

Jean‐Yves Reginster

Abstract

In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).

Topics & Keywords

Bone Metabolism and Diseases Cytokine Signaling Pathways and Interactions Cell Adhesion Molecules Research

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 5, pp. 412-420

DOI: 10.1056/nejmoa1305224

Field-Weighted Citation Impact: 66.91

Command Palette

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

Authors

Abstract

Topics & Keywords

Publication Details